NTHI — Neonc Technologies Holdings, Inc.
$3.27+10.85%
Last close: · regular session
After-hours $3.28 +0.31% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NTHI in the TickerWise workspace.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 8
- Website: https://www.neonctech.com
Latest SEC filings for NTHI
- 424B5
- D
- EFFECT
- 424B5
- S-3
- SCHEDULE 13G
- 10-K/A
- 8-K
- EFFECT
- 8-K
Latest NTHI news
- NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Read article
- NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors Read article
- NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development Read article
- NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer Read article
- NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt Read article
- NeOnc's Powerful Brain Cancer Pipeline Advances Read article
- Powerful NeOnc Brain Cancer Pipeline Advances Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.